Try a new search

Format these results:

Searched for:

person:doanl01

in-biosketch:true

Total Results:

51


Opioid Dose, Duration, and Risk of Use Disorder in Medicaid Patients With Musculoskeletal Pain

Perry, Allison; Krawczyk, Noa; Samples, Hillary; Martins, Silvia S; Hoffman, Katherine; Williams, Nicholas T; Hung, Anton; Ross, Rachael; Doan, Lisa; Rudolph, Kara E; Cerdá, Magdalena
OBJECTIVE:The CDC recommends initiating opioids for pain treatment at the lowest effective dose and duration. We examine how interactions between dose, duration, and other medication factors (e.g., drug type) influence opioid use disorder (OUD) risk-a gap not considered by CDC guidelines. SUBJECTS/METHODS:Using Medicaid claims data (2016-2019) from 25 states, we analyzed opioid-naïve adults, newly diagnosed with musculoskeletal pain who initiated opioids within three months of diagnosis. A 6-month washout confirmed no prior opioid exposure or musculoskeletal diagnosis. METHODS:Initial opioids were categorized by "dose-days supplied" (low [>0-20 mg MME] to very high [>90 mg MME] dose, and short [1-7 days] to moderate [>7-30 days] supply), and by opioid type; physical therapy (PT) sessions were also recorded. Using Poisson regression models, we estimated the OUD risk associated with dose-days categories, adjusting for baseline demographics, clinical characteristics, and medications. We separately examined opioid dose-days and PT, and assessed PT's moderating effect on dose-days' impact. RESULTS:Among 30,536 patients, half initiated opioids at 20-50 MME for 1-7 days, and 20% received PT. OUD risk was 2-3 times higher for opioids initiated for >7-30 days compared to 1-7 days across doses, and 5.5 times higher for opioids initiated for >7-30 days at > 90 MME versus 1-7 days at < 20 MME. PT alone, neither affected OUD risk nor mitigated the increased risk from longer or higher-dose opioids. CONCLUSIONS:Our findings support the need for careful opioid prescribing and alternative pain management strategies, as the observed associations between initial prescription characteristics and OUD were not mitigated by adjunctive PT. PERSPECTIVE/CONCLUSIONS:This study demonstrated that initial opioid prescriptions of 7-30 days, especially above 90 MME/day, increased OUD risk in opioid-naïve patients with musculoskeletal pain; physical therapy did not mitigate the risk. Different opioids posed varied risks, even at the same dose and duration. Careful prescribing and alternative pain management are essential.
PMID: 40581761
ISSN: 1526-4637
CID: 5887402

Low Frequency Oscillations in the Medial Orbitofrontal Cortex Mediate Widespread Hyperalgesia Across Pain Conditions

Park, Hyung G; Kenefati, George; Rockholt, Mika M; Ju, Xiaomeng; Wu, Rachel R; Chen, Zhen Sage; Gonda, Tamas A; Wang, Jing; Doan, Lisa V
Widespread hyperalgesia, characterized by pain sensitivity beyond the primary pain site, is a common yet under-characterized feature across chronic pain conditions, including chronic pancreatitis (CP). In this exploratory study, we identified a candidate neural biosignature of widespread hyperalgesia using high-density electroencephalography (EEG) in patients with chronic low back pain (cLBP). Specifically, stimulus-evoked delta, theta, and alpha oscillatory activity in the bilateral medial orbitofrontal cortex (mOFC) differentiated cLBP patients with widespread hyperalgesia from healthy controls. To examine cross-condition generalizability and advance predictive biomarker development for CP, we applied this mOFC-derived EEG biosignature to an independent cohort of patients with CP. The biosignature distinguished CP patients with widespread hyperalgesia and predicted individual treatment responses to peripherally targeted endoscopic therapy. These preliminary findings provide early support for a shared cortical signature of central sensitization across pain conditions and offer translational potential for developing EEG-based predictive tools for treatment response in CP.
PMCID:12204252
PMID: 40585147
CID: 5887502

The effectiveness of fluoroscopically guided lumbar facet steroid joint injections: A systematic review

Fogarty, Alexandra E; Buttner, Jordan A; Duszynski, Belinda; McKenna, Michael J; Miller, David C; Gonzalez-Cota, Alan; Avila, Arsenio; Vaynberg, Eduard; Sheth, Samir; Conger, Aaron; Doan, Lisa V; Ehsanian, Reza
SUMMARY OF BACKGROUND DATA/UNASSIGNED:Facet joint degeneration is a known source of chronic axial low back pain, and intra-articular steroid injections (IASI) have been used as a treatment. OBJECTIVES/UNASSIGNED:To systematically review the evidence of the effectiveness of fluoroscopically guided lumbar IASI for the treatment of lumbar facet joint pain. METHODS/UNASSIGNED:The primary outcome was ≥50 % pain reduction at ≥ 1 month, measured by Visual Analog Scale and/or Numeric Rating Scale. Secondary outcomes included ≥30 % functional improvement on a validated functional scale. Studies including group mean improvements in pain/function without categorical reporting were also considered. Two reviewers independently screened Embase, Cochrane, PubMed Medline, Ovid Medline, Web of Knowledge, and Google Scholar. The risk of bias was assessed using the Cochrane Risk of Bias Tool, and evidence quality was evaluated using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE). RESULTS/UNASSIGNED:Of the 701 publications screened, 21 met the inclusion criteria. Success rates for clinically significant pain reduction (≥50 % pain relief) ranged from 13 to 74 %, and functional improvement (≥30 % improvement) was 29 % at ≥ 1 month, based on only one study. Overall, mean improvement ranged from 11 to 59 % for pain relief and 8-58 % for function at ≥ 1 month. In the seven studies selecting patients with facet or medial branch blocks, success rates for clinically significant pain reduction (≥50 % pain relief) are reported as 13-74 % at ≥ 1 month. In this subgroup, mean pain improvement rates ranged from 23 to 67 % and functional improvement from 15 to 58 % at ≥ 1 month. According to GRADE, the overall quality of the evidence is very low due to the high risk of bias, study heterogeneity, and inconsistent methodologies. DISCUSSION/CONCLUSION/UNASSIGNED:Pragmatic and observational studies suggest IASI may reduce pain and disability, while sham-controlled trials have not demonstrated efficacy. Given the very low quality of evidence, the true effect of IASI is highly uncertain. Further high-quality, placebo-controlled studies using standardized diagnostic criteria are needed.
PMCID:12136829
PMID: 40469068
ISSN: 2772-5944
CID: 5862602

Mediation of chronic pain and disability on opioid use disorder risk by pain management practices among adult Medicaid patients, 2016-2019

Rudolph, Kara E; Inose, Shodai; Williams, Nicholas T; Hoffman, Katherine L; Forrest, Sarah E; Ross, Rachael K; Milazzo, Floriana; Díaz, Iván; Doan, Lisa; Samples, Hillary; Olfson, Mark; Crystal, Stephen; Cerdá, Magdalena; Gao, Y Nina
We estimated the extent to which different pain management practices, considered together as well as individually, mediated the relationship between chronic pain or physical disability and new-onset opioid use disorder (OUD) in a large cohort of adult Medicaid patients. Considering the plausibility of the assumptions required to identify different mediational estimands, we estimated natural indirect effects when considering mediation through the group of mediators together and estimated interventional indirect effects when considering mediation through each pain management practice individually. We estimated each effect using a nonparametric one-step estimator. The pain management variables we examined mediated all of the total effect of chronic pain on OUD risk and nearly half of the total effect of physical disability on OUD risk. High-dose, long-duration opioid prescribing and co-prescription of opioids with benzodiazepines, gabapentinoids, and muscle relaxants each contributed substantially to the increased risk of OUD due to chronic pain (contributing to 10-37% of the overall effect) and more moderately to the increased risk of OUD due to physical disability (contributing to 3-19% of the overall effect). Antidepressant or anti-inflammatory prescribing and physical therapy generally did not contribute to increased OUD risk, and, in some cases, even contributed to small reductions in risk.
PMID: 40312832
ISSN: 1476-6256
CID: 5834302

Safety practices for interventional pain procedures: Facet interventions

Klessinger, Stephan; Schuster, Nathaniel; MacVicar, John; Miller, David C; McKenna, Michael; Vorobeychik, Yakov; Popescu, Adrian; McCormick, Zachary L; Doan, Lisa; Hambraues, Johan; Waring, Patrick H; Zhao, Zirong; Boies, Brian; Nagpal, Ameet; ,
PMCID:11910088
PMID: 40092622
ISSN: 2772-5944
CID: 5812992

The Use of Electronic Consent (eConsent) Within the Ketamine for Long-Lasting Pain Relief After Surgery (KALPAS) Multicenter Trial

Doan, Lisa V; Burr, Jeri; Perez, Raven; Martinez, Hamleini; Cuevas, Randy; Watt, Kevin; Wang, Jing
BACKGROUND/UNASSIGNED:The informed consent process has traditionally taken place in person. The introduction of electronic consent (eConsent) has made remote consenting processes possible. Use of eConsent has increased since the COVID-19 pandemic. It has streamlined the process of consenting patients and has been shown to benefit the research study team and participants. ECONSENT IN THE KETAMINE ANALGESIA FOR LONG-LASTING PAIN RELIEF AFTER SURGERY KALPAS STUDY/UNASSIGNED:The KALPAS study is a multicenter, double-blind, randomized controlled study investigating the effectiveness of ketamine in reducing chronic post-mastectomy pain in women undergoing mastectomy for oncologic indication. The study uses a two-part consent form consisting of a master consent with information applicable to all sites and site-specific information. All potential participants receive the full two-part consent form for review. When signing the eConsent, however, all potential participants are provided with a concise summary of the informed consent document, an approach not widely used by multicenter studies. eConsent has been noted to be beneficial to research staff when trying to gather informed consent from participants who live far away from the hospital, want to include their family and friends, and for researchers who can approach patients outside of their clinical appointments. CONCLUSION/UNASSIGNED:The ability to consent patients remotely has allowed for a flexible workflow within sites and a more patient-centric process that focuses on including loved ones in the discussion and scheduling time to speak to a principal investigator. Demand for eConsent will likely continue in the post-COVID era, and use of a concise summary can allow for a more efficient consenting process.
PMCID:11808973
PMID: 39931425
ISSN: 1178-7090
CID: 5793292

Pain Management Treatments and Opioid Use Disorder Risk in Medicaid Patients

Rudolph, Kara E; Williams, Nicholas T; Diaz, Ivan; Forrest, Sarah; Hoffman, Katherine L; Samples, Hillary; Olfson, Mark; Doan, Lisa; Cerda, Magdalena; Ross, Rachael K
INTRODUCTION/BACKGROUND:People with chronic pain are at increased risk of opioid misuse. Less is known about the unique risk conferred by each pain management treatment, as treatments are typically implemented together, confounding their independent effects. This study estimated the extent to which pain management treatments were associated with risk of opioid use disorder (OUD) for those with chronic pain, controlling for baseline demographic and clinical confounding variables and holding other pain management treatments at their observed levels. METHODS:Data were analyzed in 2024 from 2 chronic pain subgroups within a cohort of non-pregnant Medicaid patients aged 35-64 years, 2016-2019, from 25 states: those with (1) chronic pain and physical disability (CPPD) (N=6,133) or (2) chronic pain without disability (CP) (N=67,438). Nine pain management treatments were considered: prescription opioid (1) dose and (2) duration; (3) number of opioid prescribers; opioid co-prescription with (4) benzo- diazepines, (5) muscle relaxants, and (6) gabapentinoids; (7) nonopioid pain prescription, (8) physical therapy, and (9) other pain treatment modality. The outcome was OUD risk. RESULTS:Having opioids co-prescribed with gabapentin or benzodiazepine was statistically significantly associated with a 37-45% increased OUD risk for the CP subgroup. Opioid dose and duration also were significantly associated with increased OUD risk in this subgroup. Physical therapy was significantly associated with an 18% decreased risk of OUD in the CP subgroup. DISCUSSION/CONCLUSIONS:Coprescription of opioids with either gabapentin or benzodiazepines may substantially increase OUD risk. More positively, physical therapy may be a relatively accessible and safe pain management strategy.
PMID: 39025248
ISSN: 1873-2607
CID: 5695952

Multiorganizational consensus to define guiding principles for perioperative pain management in patients with chronic pain, preoperative opioid tolerance, or substance use disorder

Dickerson, David M; Mariano, Edward R; Szokol, Joseph W; Harned, Michael; Clark, Randall M; Mueller, Jeffrey T; Shilling, Ashley M; Udoji, Mercy A; Mukkamala, S Bobby; Doan, Lisa; Wyatt, Karla E K; Schwalb, Jason M; Elkassabany, Nabil M; Eloy, Jean D; Beck, Stacy L; Wiechmann, Lisa; Chiao, Franklin; Halle, Steven G; Krishnan, Deepak G; Cramer, John D; Ali Sakr Esa, Wael; Muse, Iyabo O; Baratta, Jaime; Rosenquist, Richard; Gulur, Padma; Shah, Shalini; Kohan, Lynn; Robles, Jennifer; Schwenk, Eric S; Allen, Brian F S; Yang, Stephen; Hadeed, Josef G; Schwartz, Gary; Englesbe, Michael J; Sprintz, Michael; Urish, Kenneth L; Walton, Ashley; Keith, Lauren; Buvanendran, Asokumar
Significant knowledge gaps exist in the perioperative pain management of patients with a history of chronic pain, substance use disorder, and/or opioid tolerance as highlighted in the US Health and Human Services Pain Management Best Practices Inter-Agency Task Force 2019 report. The report emphasized the challenges of caring for these populations and the need for multidisciplinary care and a comprehensive approach. Such care requires stakeholder alignment across multiple specialties and care settings. With the intention of codifying this alignment into a reliable and efficient processes, a consortium of 15 professional healthcare societies was convened in a year-long modified Delphi consensus process and summit. This process produced seven guiding principles for the perioperative care of patients with chronic pain, substance use disorder, and/or preoperative opioid tolerance. These principles provide a framework and direction for future improvement in the optimization and care of 'complex' patients as they undergo surgical procedures.
PMID: 37185214
ISSN: 1532-8651
CID: 5544112

Clinical pain management: Current practice and recent innovations in research

Wang, Jing; Doan, Lisa V
Chronic pain affects one in five adults. It is not only a major cause of disability for individual patients but also a driver of costs for entire healthcare systems. Treatment of pain remains a challenge, and the use of opioids has further led to a concurrent opioid epidemic. In this review, we discuss current standard treatment options for chronic pain, including pharmacological, behavioral, and interventional treatments. In addition, we review ongoing research in different areas that will potentially unlock new therapies.
PMID: 39383871
ISSN: 2666-3791
CID: 5706162

Prevention of Post-Mastectomy Pain Syndrome: A Review of Recent Literature on Perioperative Interventions

Wu, Rachel R; Katz, Simon; Wang, Jing; Doan, Lisa V
PURPOSE OF REVIEW/OBJECTIVE:Up to 60% of breast cancer patients continue to experience pain three months or more after surgery, with 15 to 25% reporting moderate to severe pain. Post-mastectomy pain syndrome (PMPS) places a high burden on patients. We reviewed recent studies on perioperative interventions to prevent PMPS incidence and severity. RECENT FINDINGS/RESULTS:Recent studies on pharmacologic and regional anesthetic interventions were reviewed. Only nine of the twenty-three studies included reported a significant improvement in PMPS incidence and/or severity, sometimes with mixed results for similar interventions. Evidence for prevention of PMPS is mixed. Further investigation of impact of variations in dosing is warranted. In addition, promising newer interventions for prevention of PMPS such as cryoneurolysis of intercostal nerves and stellate ganglion block need confirmatory studies.
PMID: 38814502
ISSN: 1534-6269
CID: 5663762